| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 65219-0668-01 | 65219-0668 | Denosumab | CONEXXENCE | 60.0 mg/mL | Immunotherapy | Monoclonal Antibody | RANKL | Subcutaneous | Jun 30, 2025 | In Use | |
| 72579-0121-01 | 72579-0121 | Tislelizumab, Tislelizumab-jsgr | TEVIMBRA | 10.0 mg/mL | Immunotherapy | Checkpoint Inhibitor | PD-1 | Intravenous | Mar 14, 2024 | In Use | |
| 83654-0105-01 | 83654-0105 | Penpulimab | Penpulimab | 100.0 mg/10mL | Immunotherapy | Monoclonal Antibody | PD-1 | Intravenous | Apr 23, 2025 | In Use | |
| 00004-0352-30 | 00004-0352 | Peginterferon alfa-2a | Pegasys | Immunotherapy | Cytokine | Interferon | Feb 22, 2011 | Aug 22, 2011 | No Longer Used | ||
| 00085-4347-01 | 00085-4347 | Peginterferon alfa-2b | Sylatron | Immunotherapy | Cytokine | Interferon | Aug 30, 2014 | Oct 18, 2020 | In Use | ||
| 69097-0381-73 | 69097-0381 | Lenalidomide | Lenalidomide | 5.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 6, 2022 | In Use | |
| 57894-0111-02 | 57894-0111 | ciltacabtagene autoleucel | CARVYKTI | 100000000.0 1/1 | Immunotherapy | CAR-T | BCMA | Intravenous | Feb 28, 2022 | In Use | |
| 00115-1476-59 | 00115-1476 | Imiquimod | Imiquimod | 50.0 mg/g | Immunotherapy | Immunomodulator | Dermatological Agent | Topical | Feb 28, 2011 | Jun 1, 2017 | No Longer Used |
| 00004-0352-98 | 00004-0352 | Peginterferon alfa-2a | Pegasys | Immunotherapy | Cytokine | Interferon | Oct 16, 2002 | Jul 31, 2015 | No Longer Used | ||
| 55513-0132-21 | 55513-0132 | trastuzumab-anns | Kanjinti | 420.0 mg/20mL | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Jul 1, 2025 | In Use | |
| 63304-0044-01 | 63304-0044 | Lenalidomide | Lenalidomide | 15.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 4, 2023 | In Use | |
| 70771-1680-01 | 70771-1680 | LENALIDOMIDE | LENALIDOMIDE | 20.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 7, 2023 | In Use | |
| 59572-0515-01 | 59572-0515 | idecabtagene vicleucel | Abecma | 300000000.0 1/1 | Immunotherapy | CAR-T | BCMA | Intravenous | Mar 26, 2021 | In Use | |
| 78206-0148-01 | 78206-0148 | Ontruzant | Ontruzant | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Jun 1, 2021 | In Use | ||
| 63304-0041-01 | 63304-0041 | Lenalidomide | Lenalidomide | 2.5 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 12, 2023 | In Use | |
| 00004-0365-09 | 00004-0365 | Peginterferon alfa-2a | Pegasys | 180.0 ug/.5mL | Immunotherapy | Cytokine | Interferon | Subcutaneous | Nov 1, 2011 | In Use | |
| 00002-7669-01 | 00002-7669 | Ramucirumab | Cyramza | 10.0 mg/mL | Immunotherapy | Monoclonal Antibody | VEGF | Intravenous | Apr 21, 2014 | In Use | |
| 59572-0504-00 | 59572-0504 | Pomalidomide | Pomalyst | 4.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Feb 18, 2013 | In Use | |
| 69448-0015-05 | 69448-0015 | Trastuzumab-strf | HERCESSI | 150.0 mg/7.4mL | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Jan 1, 2025 | In Use | |
| 72606-0011-10 | 72606-0011 | Bevacizumab-adcd | Vegzelma | 100.0 mg/4mL | Immunotherapy | Monoclonal Antibody | VEGFR | Intravenous | Apr 3, 2023 | In Use | |
| 69097-0604-73 | 69097-0604 | Lenalidomide | Lenalidomide | 2.5 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 9, 2023 | In Use | |
| 59572-0215-13 | 59572-0215 | Thalidomide | Thalomid | 150.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 20, 2007 | In Use | |
| 00074-1055-01 | 00074-1055 | Telisotuzumab Vedotin | EMRELIS | 100.0 mg/mL | Immunotherapy | Drug Antibody Conjugate | c-MET | Intravenous | May 14, 2025 | In Use | |
| 31722-0260-01 | 31722-0260 | LENALIDOMIDE | LENALIDOMIDE | 15.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | May 11, 2023 | In Use | |
| 50242-0105-01 | 50242-0105 | polatuzumab vedotin | POLIVY | 140.0 mg/7.52mL | Immunotherapy | Drug Antibody Conjugate | CD79b | Intravenous | Jun 10, 2019 | In Use |
Found 11888 results — Export these results
Home